

Faculty disclosures

Disclosure Statements

It is the policy of the American Academy of CME, Inc. to ensure balance, independence, objectivity and scientific rigor in all sponsored educational activities. Any and all financial relationships between faculty and the manufacturer of any product or device being discussed are disclosed by the faculty. Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide registrants with information that might be of potential importance to their evaluation of a given talk. Discussion of any product or device not approved by the Food and Drug Administration (FDA) shall be made known to the audience.

Because not all of the products discussed may be reimbursed in all states, please refer to your state's Medicare/Medicaid reimbursement policies.

The Lupus Foundation of America, Inc., as the educational partner to the American Academy of CME, Inc., wishes to disclose an ongoing relationship with Aspreva Pharmaceuticals. The Lupus Foundation of America has received educational grant funds from Aspreva Pharmaceuticals for the creation of continuing education materials.

The following speakers have reported receiving something of value* from a company whose product may be germane to the content of their presentations:

Jill P. Buyon, MD,
Professor of Medicine, New York University School of Medicine;
Director of Lupus Clinic, Hospital for Joint Disease, New York, NY

Research Support: Prometheus Laboratories

Consultant: Amgen, Aspreva, Bristol-Myers Squibb, Lilly, Genentech, Johnson & Johnson, La Jolla Pharmaceutical, Pfizer

Joan T. Merrill, MD,
Medical Director, Lupus Foundation of America; University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation

Research Support: Abbott, Amgen, Biogen, DuPont, FDA, Genelabs, Human Genome Sciences, IDEC, La Jolla Pharmaceutical, NABI, National Institutes of Health, Otsuka, SLICC Consortium

Consultant: Abbott, Biogen, Bio-Rad, Bristol-Myers Squibb, Centocor, Genelabs, Genentech, Human Genome Sciences, IDEC, Immunomedics, La Jolla Pharmaceutical, Medarex, MedImmune, Otsuka, Teva, Wyeth

The Lupus Foundation of America

Victoria P. Werth, MD,
Professor of Dermatology and Medicine, University of Pennsylvania, Chief
Philadelphia V.A. Medical Center, Philadelphia, PA

Research Support: Celgene, Centocor, Proctor & Gamble

Consultant: Celgene, Centocor, Pfizer

Gerald B. Appel, MD,
Professor of Medicine, Division of Nephrology, Columbia University College of
Physicians and Surgeons, New York, NY

Research Support: AstraZeneca, Genentech, La Jolla Pharmaceutical, Merck, Pfizer, Roche.

Consultant: Genentech, La Jolla Pharmaceutical, Merck, Pfizer, Roche

Speaker's Bureau: AstraZeneca, La Jolla Pharmaceutical, Merck, Pfizer, Roche

* « Something of Value » refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for education services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure in keeping with the spirit of the stated policy.

The following speakers intend to discuss non-FDA-approved or investigational uses of pharmaceutical products:

Dr. Merrill: anti-BlyS, CTLA4lg, dehydroepiandrosterone, LJP 394, mycophenolate mofetil and rituximab for treatment of lupus. In addition Dr Merrill will discuss Adacolumn, anti-CD40L, azathioprine, bolus steroids, cyclophosphamide, danazol, leflunomide, LJP1082, lumphostat B, methotrexate and pheresis protocols.

Dr. Buyon: azathioprine, cyclophosphamide, hydroxychloroquine and mycophenolate mofetil for the treatment of lupus, as well as dehydroepiandrosterone and antitumor necrosis factor antibodies for arthritis.

Dr. Werth: anti-adhesion molecules, anti-CTLA4, antimalarials, azathioprine, chemokine antagonists, dapsone, methotrexate, mycophenolate mofetil, pimecrolimus, retinoids, rituximab, tacrolimus, thalidomide and tumor necrosis factor – cutaneous lupus erythematosus.

Dr. Appel: anti-CD40, anti-C5, anti-interferon-anti-CD20, anti-IL-10, azathioprine, cyclophosphamide, cyclosporin-A, hydroxychloroquine, LJP 394 and mycophenolate mofetil for lupus nephritis.